What is Telmisan-Mepha?
Telmisan-Mepha is used alone or together with other medicines to treat high blood pressure (hypertension). High blood pressure adds to the workload of the heart and arteries. If it continues for a long time, the heart and arteries may not function properly. This can damage the blood vessels of the brain, heart, and kidneys, resulting in a stroke, heart failure, or kidney failure. Lowering blood pressure can reduce the risk of strokes and heart attacks.
Telmisan-Mepha is also used to lower the risk of heart attacks or stroke in patients 55 years of age and older who have diabetes or heart problems.
Telmisan-Mepha is an angiotensin II receptor blocker (ARB). It works by blocking a substance in the body that causes blood vessels to tighten. As a result, Telmisan-Mepha relaxes the blood vessels. This lowers blood pressure and increases the supply of blood and oxygen to the heart.
Telmisan-Mepha is available only with your doctor's prescription.
Telmisan-Mepha indications
Hypertension: Treatment of essential hypertension.
Cardiovascular Risk Reduction: Telmisan-Mepha is indicated for reduction of the risk of myocardial infarction, stroke, or death from cardiovascular causes in patients 55 years of age or older at high risk of developing major cardiovascular events who are unable to take ACE inhibitors.
High risk of cardiovascular events can be evidenced by history of coronary artery disease, peripheral arterial disease, stroke, transient ischemic attack, or high-risk diabetes (insulin-dependent or non-insulin dependent) with evidence of end-organ damage. Telmisan-Mepha can be used in additional to other needed treatment (such as antihypertensive, antiplatelet or lipid-lowering therapy).
Studies of Telmisan-Mepha in this setting do not exclude that it may not preserve a meaningful fraction of the effect of the ACE inhibitor to which it was compared. Consider using the ACE inhibitor first, and, if it is stopped for cough only, consider re-trying the ACE inhibitor after the cough resolves.
Use of Telmisan-Mepha with an ACE inhibitor is not recommended.
How should I use Telmisan-Mepha?
Use Telmisan-Mepha as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- An extra patient leaflet is available with Telmisan-Mepha. Talk to your pharmacist if you have questions about this information.
- Take Telmisan-Mepha by mouth with or without food.
- Do not remove the tablet from the blister seal until you are ready to take your dose.
- Take Telmisan-Mepha on a regular schedule to get the most benefit from it. Taking Telmisan-Mepha at the same time each day will help you remember to take it.
- Continue to take Telmisan-Mepha even if you feel well. Do not miss any doses.
- If you miss a dose of Telmisan-Mepha, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.
Ask your health care provider any questions you may have about how to use Telmisan-Mepha.
Uses of Telmisan-Mepha in details
Telmisan-Mepha belongs to a class of medicines known as angiotensin II receptor blockers. It is used to treat high blood pressure, prevention and treatment of heart attack (myocardial Infarction) and heart failure; when heart is unable to pump sufficient blood. It is also used for kidney failure in patients with diabetes.
Telmisan-Mepha description
Telmisan-Mepha is an angiotensin II receptor antagonist (ARB) used in the management of hypertension. Generally, angiotensin II receptor blockers (ARBs) such as Telmisan-Mepha bind to the angiotensin II type 1 (AT1) receptors with high affinity, causing inhibition of the action of angiotensin II on vascular smooth muscle, ultimately leading to a reduction in arterial blood pressure. Recent studies suggest that Telmisan-Mepha may also have PPAR-gamma agonistic properties that could potentially confer beneficial metabolic effects.
Telmisan-Mepha dosage
Telmisan-Mepha Dosage
Generic name: Telmisan-Mepha 20mg
Dosage form: tablet
The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.
2.1 Hypertension
Dosage must be individualized. The usual starting dose of Telmisan-Mepha tablets is 40 mg once a day. Blood pressure response is dose-related over the range of 20 to 80 mg.
Most of the antihypertensive effect is apparent within 2 weeks and maximal reduction is generally attained after 4 weeks. When additional blood pressure reduction beyond that achieved with 80 mg Telmisan-Mepha is required, a diuretic may be added.
No initial dosage adjustment is necessary for elderly patients or patients with renal impairment, including those on hemodialysis. Patients on dialysis may develop orthostatic hypotension; their blood pressure should be closely monitored.
Telmisan-Mepha tablets may be administered with other antihypertensive agents.
Telmisan-Mepha tablets may be administered with or without food.
2.2 Cardiovascular Risk Reduction
The recommended dose of Telmisan-Mepha tablets is 80 mg once a day and can be administered with or without food. It is not known whether doses lower than 80 mg of Telmisan-Mepha are effective in reducing the risk of cardiovascular morbidity and mortality.
When initiating Telmisan-Mepha therapy for cardiovascular risk reduction, monitoring of blood pressure is recommended, and if appropriate, adjustment of medications that lower blood pressure may be necessary.
More about Telmisan-Mepha (Telmisan-Mepha)
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Images
- Drug Interactions
- Support Group
- Pricing & Coupons
- En Espanol
- 25 Reviews - Add your own review/rating
- Generic Availability
Consumer resources
- Telmisan-Mepha
- Telmisan-Mepha (Advanced Reading)
Professional resources
- Telmisan-Mepha (AHFS Monograph)
- Telmisan-Mepha (FDA)
Other formulations
- Telmisan-Mepha HCT
Related treatment guides
- Cardiovascular Risk Reduction
- High Blood Pressure
- Prevention of Cardiovascular Disease
Telmisan-Mepha interactions
See also:
What other drugs will affect Telmisan-Mepha?
Aliskiren: Do not co-administer aliskiren with Telmisan-Mepha in patients with diabetes. Avoid use of aliskiren with Telmisan-Mepha in patients with renal impairment (GFR < 60 mL/min).
Digoxin: When Telmisan-Mepha was co-administered with digoxin, median increases in digoxin peak plasma concentration (49%) and in trough concentration (20%) were observed. Therefore, monitor digoxin levels when initiating, adjusting, and discontinuing Telmisan-Mepha for the purpose of keeping the digoxin level within the therapeutic range.
Lithium: Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with angiotensin II receptor antagonists including Telmisan-Mepha. Therefore, monitor serum lithium levels during concomitant use.
Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors): In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, co-administration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists, including Telmisan-Mepha, may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible. Monitor renal function periodically in patients receiving Telmisan-Mepha and NSAID therapy.
The antihypertensive effect of angiotensin II receptor antagonists, including Telmisan-Mepha may be attenuated by NSAIDs including selective COX-2 inhibitors.
Ramipril and Ramiprilat: Co-administration of Telmisan-Mepha 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3-and 2.1-fold, respectively, and Cmax and AUC of ramiprilat 2.4-and 1.5-fold, respectively. In contrast, Cmax and AUC of Telmisan-Mepha decrease by 31% and 16%, respectively. When co-administering Telmisan-Mepha and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of Telmisan-Mepha. Concomitant use of Telmisan-Mepha and ramipril is not recommended.
Other Drugs: Co-administration of Telmisan-Mepha did not result in a clinically significant interaction with acetaminophen, amlodipine, glyburide, simvastatin, hydrochlorothiazide, warfarin, or ibuprofen. Telmisan-Mepha is not metabolized by the cytochrome P450 system and had no effects in vitro on cytochrome P450 enzymes, except for some inhibition of CYP2C19. Telmisan-Mepha is not expected to interact with drugs that inhibit cytochrome P450 enzymes; it is also not expected to interact with drugs metabolized by cytochrome P450 enzymes, except for possible inhibition of the metabolism of drugs metabolized by CYP2C19.
Telmisan-Mepha side effects
See also:
What are the possible side effects of Telmisan-Mepha?
The following adverse reaction is described elsewhere in labeling:
Renal dysfunction upon use with ramipril
Clinical Trials Experience
Because clinical studies are conducted under widely varying conditions, adverse reactions rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.
Hypertension
Telmisan-Mepha has been evaluated for safety in more than 3700 patients, including 1900 treated for over 6 months and more than 1300 for over one year. Adverse experiences have generally been mild and transient in nature and have infrequently required discontinuation of therapy.
In placebo-controlled trials involving 1041 patients treated with various doses of Telmisan-Mepha (20 to 160 mg) monotherapy for up to 12 weeks, the overall incidence of adverse events was similar to that in patients treated with placebo.
Adverse events occurring at an incidence of ≥1% in patients treated with Telmisan-Mepha and at a greater rate than in patients treated with placebo, irrespective of their causal association, are presented in Table 1.
Table 1 Adverse Events Occurring at an Incidence of ≥1% in Patients Treated with Telmisan-Mepha and at a Greater Rate Than Patients Treated with Placebo
| Telmisan-Mepha n=1455 % | Placebo n=380 % | |
| Upper respiratory tract infection | 7 | 6 |
| Back pain | 3 | 1 |
| Sinusitis | 3 | 2 |
| Diarrhea | 3 | 2 |
| Pharyngitis | 1 | 0 |
In addition to the adverse events in the table, the following events occurred at a rate of ≥1% but were at least as frequent in the placebo group: influenza-like symptoms, dyspepsia, myalgia, urinary tract infection, abdominal pain, headache, dizziness, pain, fatigue, coughing, hypertension, chest pain, nausea, and peripheral edema. Discontinuation of therapy because of adverse events was required in 2.8% of 1455 patients treated with Telmisan-Mepha tablets and 6.1% of 380 placebo patients in placebo-controlled clinical trials.
The incidence of adverse events was not dose-related and did not correlate with gender, age, or race of patients.
The incidence of cough occurring with Telmisan-Mepha in 6 placebo-controlled trials was identical to that noted for placebo-treated patients (1.6%).
In addition to those listed above, adverse events that occurred in more than 0.3% of 3500 patients treated with Telmisan-Mepha monotherapy in controlled or open trials are listed below. It cannot be determined whether these events were causally related to Telmisan-Mepha tablets:
Autonomic Nervous System: impotence, increased sweating, flushing; Body as a Whole: allergy, fever, leg pain, malaise; Cardiovascular: palpitation, dependent edema, angina pectoris, tachycardia, leg edema, abnormal ECG; CNS: insomnia, somnolence, migraine, vertigo, paresthesia, involuntary muscle contractions, hypoesthesia; Gastrointestinal: flatulence, constipation, gastritis, vomiting, dry mouth, hemorrhoids, gastroenteritis, enteritis, gastroesophageal reflux, toothache, non-specific gastrointestinal disorders; Metabolic: gout, hypercholesterolemia, diabetes mellitus; Musculoskeletal: arthritis, arthralgia, leg cramps; Psychiatric: anxiety, depression, nervousness; Resistance Mechanism: infection, fungal infection, abscess, otitis media; Respiratory: asthma, bronchitis, rhinitis, dyspnea, epistaxis; Skin: dermatitis, rash, eczema, pruritus; Urinary: micturition frequency, cystitis; Vascular: cerebrovascular disorder; and Special Senses: abnormal vision, conjunctivitis, tinnitus, earache.
During initial clinical studies, a single case of angioedema was reported (among a total of 3781 patients treated).
Clinical Laboratory Findings
In placebo-controlled clinical trials, clinically relevant changes in standard laboratory test parameters were rarely associated with administration of Telmisan-Mepha tablets.
Hemoglobin: A greater than 2 g/dL decrease in hemoglobin was observed in 0.8% Telmisan-Mepha patients compared with 0.3% placebo patients. No patients discontinued therapy because of anemia.
Creatinine: A 0.5 mg/dL rise or greater in creatinine was observed in 0.4% Telmisan-Mepha patients compared with 0.3% placebo patients. One Telmisan-Mepha-treated patient discontinued therapy because of increases in creatinine and blood urea nitrogen.
Liver Enzymes: Occasional elevations of liver chemistries occurred in patients treated with Telmisan-Mepha; all marked elevations occurred at a higher frequency with placebo. No Telmisan-Mepha-treated patients discontinued therapy because of abnormal hepatic function.
Cardiovascular Risk Reduction
Because common adverse reactions were well characterized in studies of Telmisan-Mepha in hypertension, only adverse events leading to discontinuation and serious adverse events were recorded in subsequent studies of Telmisan-Mepha for cardiovascular risk reduction. In TRANSCEND (N=5926, 4 years and 8 months of follow-up), discontinuations for adverse events were 8.4% on Telmisan-Mepha and 7.6% on placebo. The only serious adverse events at least 1% more common on Telmisan-Mepha than placebo were intermittent claudication (7% vs 6%) and skin ulcer (3% vs 2%).
Postmarketing Experience
The following adverse reactions have been identified during post-approval use of Telmisan-Mepha. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate reliably their frequency or establish a causal relationship to drug exposure. Decisions to include these reactions in labeling are typically based on one or more of the following factors: (1) seriousness of the reaction, (2) frequency of reporting, or (3) strength of causal connection to Telmisan-Mepha.
The most frequent spontaneously reported events include: headache, dizziness, asthenia, coughing, nausea, fatigue, weakness, edema, face edema, lower limb edema, angioneurotic edema, urticaria, hypersensitivity, sweating increased, erythema, chest pain, atrial fibrillation, congestive heart failure, myocardial infarction, blood pressure increased, hypertension aggravated, hypotension (including postural hypotension), hyperkalemia, syncope, dyspepsia, diarrhea, pain, urinary tract infection, erectile dysfunction, back pain, abdominal pain, muscle cramps (including leg cramps), myalgia, bradycardia, eosinophilia, thrombocytopenia, uric acid increased, abnormal hepatic function/liver disorder, renal impairment including acute renal failure, anemia, increased CPK, anaphylactic reaction, tendon pain (including tendonitis, tenosynovitis), drug eruption (toxic skin eruption mostly reported as toxicoderma, rash, and urticaria), hypoglycemia (in diabetic patients), and angioedema (with fatal outcome).
Rare cases of rhabdomyolysis have been reported in patients receiving angiotensin II receptor blockers, including Telmisan-Mepha.
Telmisan-Mepha contraindications
See also:
What is the most important information I should know about Telmisan-Mepha?
Hypersensitivity to Telmisan-Mepha or to any of the excipients of Telmisan-Mepha.
Biliary obstructive disorders and severe hepatic impairment.
The concomitant use with aliskiren is contraindicated in patients with diabetes mellitus or renal impairment (GFR <60 mL/min/1.73 m2).
In case of rare hereditary conditions that may be incompatible with an excipient of Telmisan-Mepha, the use of Telmisan-Mepha is contraindicated.
Use in pregnancy: The use of angiotensin II receptor antagonists is not recommended during the 1st trimester of pregnancy and should not be initiated during pregnancy.
Nonclinical studies with Telmisan-Mepha do not indicate teratogenic effect, but have shown fetotoxicity.
Angiotensin II receptor antagonist exposure during the 2nd and 3rd trimester is known to induce human fetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalemia).
Unless continued and angiotensin II receptor antagonist therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with angiotensin II receptor antagonist should be stopped immediately and if appropriate, alternative therapy should be started.
Should exposure to angiotensin II receptor antagonists have occurred from the 2nd trimester of pregnancy, ultrasound check of renal function and skull is recommended.
Infants whose mothers have taken angiotensin II receptor antagonist should be closely observed for hypotension.
Use in lactation: Telmisan-Mepha is contraindicated during lactation since it is not known whether it is excreted in human milk.
Animal studies have shown excretion of Telmisan-Mepha in breast milk.
Active ingredient matches for Telmisan-Mepha:
Telmisartan in Switzerland.
List of Telmisan-Mepha substitutes (brand and generic names) | Sort by popularity |
| Unit description / dosage (Manufacturer) | Price, USD |
| TELMISAFE | |
| Telmisafe 80mg Tablet (Lakshya Life Sciences) | $ 0.16 |
| Telmisartan (Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Costa Rica, Croatia (Hrvatska), Czech Republic, Denmark, Dominican Republic, Ecuador, El Salvador, Finland, France, Georgia, Germany, Greece, Guatemala, Honduras, Hong Kong, Hungary, Iceland, Indonesia, Ireland, Israel, Italy, Japan, Latvia, Lithuania, Luxembourg, Malaysia, Mexico, Netherlands, Nicaragua, Norway, Oman, Panama, Peru, Philippines, Poland, Romania, Russian Federation, Serbia, Singapore, Slovakia, Slovenia, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, Tunisia, Turkey, United Kingdom, United States, Venezuela, Vietnam) | |
| Tablet; Oral; Telmisartan 20 mg | |
| Tablet; Oral; Telmisartan 40 mg | |
| Tablet; Oral; Telmisartan 80 mg | |
| Micardis 30 40 mg tablet Box | $ 110.11 |
| Micardis HCT 30 40-12.5 mg tablet Box | $ 106.34 |
| Micardis HCT 30 80-12.5 mg tablet Box | $ 106.18 |
| Micardis 30 80 mg tablet Box | $ 103.92 |
| Micardis HCT 30 80-25 mg tablet Box | $ 100.48 |
| Micardis 30 20 mg tablet Box | $ 99.70 |
| Micardis 20 mg tablet | $ 3.29 |
| Micardis hct 40-12.5 mg tablet | $ 3.29 |
| Micardis hct 80-12.5 mg tablet | $ 3.29 |
| Micardis hct 80-25 mg tablet | $ 3.29 |
| Micardis 40 mg tablet | $ 2.24 |
| Micardis 80 mg tablet | $ 2.24 |
| Telmisartan tablet 20 mg/1 (Roxane Laboratories, Inc. (US)) | |
| Telmisartan tablet 80 mg (Pharmascience Inc (Canada)) | |
| Telmisartan tablet 40 mg (Pro Doc Limitee (Canada)) | |
| Telmisartan tablet 40 mg/1 (Roxane Laboratories, Inc. (US)) | |
| Telmisartan tablet 80 mg/1 (Roxane Laboratories, Inc. (US)) | |
| Telmisartan +pharma (Poland) | |
| Telmisartan - 1 A Pharma (Germany) | |
| Telmisartan - South Ocean Pharm (China) | |
| Telmisartan / Hidroclorotiazida Amsa (Mexico) | |
| Telmisartan 123ratio (Poland) | |
| TELMISARTAN 20MG TABLET | |
| TELMISARTAN 20MG TABLET 1 strip / 10 tablets each (Jan Aushadhi) | $ 0.16 |
| Telmisartan 40mg Dallas (Paraguay) | |
| TELMISARTAN 40MG TABLET | |
| TELMISARTAN 40MG TABLET 1 strip / 10 tablets each (Jan Aushadhi) | $ 0.15 |
| Telmisartan 80mg Dallas (Paraguay) | |
| Telmisartan AbZ (Germany) | |
| Telmisartan Accord Healthcare (Canada) | |
| Telmisartan Acino (Spain) | |
| Telmisartan Actavis (Netherlands) | |
| Telmisartan Actavis FC tab 40 mg 30's (Actavis) | |
| Telmisartan Actavis FC tab 80 mg 30's (Actavis) | |
| Telmisartan Actavis 40 mg (Hungary) | |
| Telmisartan Actavis 80 mg (Hungary) | |
| Telmisartan AL (Germany) | |
| Telmisartan Almus (Italy) | |
| Telmisartan Alter (Portugal) | |
| Telmisartan Amneal (Netherlands) | |
| Telmisartan Amsa (Mexico) | |
See 1793 substitutes for Telmisan-Mepha | |
References
- DailyMed. "AMLODIPINE BESYLATE; TELMISARTAN: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- PubChem. "Telmisartan". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- DrugBank. "Telmisartan". http://www.drugbank.ca/drugs/DB00966 (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Telmisan-Mepha are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Telmisan-Mepha. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yetConsumer reported time for results
No survey data has been collected yetConsumer reported age
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
